Trasylol Lawyer
Remaining Trasylol Stock Pulled from Market
Category: Trasylol News
Bayer is pulling any remaining stock of Trasylol from the market after the final results of the BART study were published in the New England Journal of Medicine yesterday. Sales of the anti-bleeding drug were halted last year after preliminary results showed a fifty percent increase in death after its use. The drug still remained in inventory at some hospitals for use in cases that met strict guidelines.
Continue reading "Remaining Trasylol Stock Pulled from Market"
78 Trasylol Lawsuits Filed
Category: Trasylol Lawsuits
The CEO of Bayer announced that they face 78 Trasylol lawsuits in the United States. He was speaking to shareholders at the time, discussing the financial situation of the company.
Trasylol Lawsuits Filed in Florida
Category: Trasylol Lawsuits
Attorneys representing clients that were harmed by the anti-bleeding drug Trasylol have filed eight lawsuits on their behalf in Florida. An unknown number of people may have suffered kidney failure and death following open heart surgery in which Trasylol was used. A study in Canada last year showed that the risk of death increased 50% for patients in which the drug was used.
Trasylol puts 10,000 Floridians at Risk
Category: Trasylol News
As more data is released, people are able to see just how widespread and devastating the effects of Trayslol are. In Florida, it is estimated that nearly 10,000 patients have either lost their lives or seriously compromised their health as a result of Trayslol. http://www.lawyersandsettlements.com/articles/10143/trasylol-10000.html According to Dr. Dennis Magano, approximately 22,000 lives could have been saved if the manufacturers of Trasylol would have taken the product off the market two years earlier than the recall. At that time, the manufacturer had enough evidence to determine that Trasylol was potentially harmful.
"Instead, Bayer is alleged to have suppressed evidence and soft-pedaled the issue in an effort to keep Trasylol on the market. It was only when faced with insurmountable evidence suggesting Trasylol was potentially harmful, that Bayer finally acted and pulled Trasylol altogether." http://www.lawyersandsettlements.com/articles/10143/trasylol-10000.html
"At its peak, Trasylol was being used in two-thirds of all open-heart surgical procedures.
Mangano estimates that over the two years between his original call for the removal of Trasylol, and when the drug was finally recalled last November 431,000 patients were administered the drug. Of those, Mangano calculates that 22,000 died. That leaves 409,000 who either were not affected by the drug, or are having to deal with a litany of health problems and adverse effects, not the least of which is renal failure, or failure of the kidney. Heart attack and stroke has also been linked to Trasylol.
What raises Viles' ire is the fact that patients are not routinely told what drugs are used during their surgery, unless the patient is proactive and request their medical records.
Therefore, patients could have been given Trasylol during the course of an open-heart surgical procedure and never know it." http://www.lawyersandsettlements.com/articles/10143/trasylol-10000.html
1,000 People Died Each Month From Trasylol
Category: Trasylol News
A researcher that was responsible for such important work as discovering a daily aspirin can reduce the risk of heart attack has stated that 1,000 people a month have died when Trasylol was being used regularly. Trasylol is a drug used in open heart bypass surgery to reduce the amount of blood lost. Studies performed on patient data has shown an increased risk of kidney failure from Trasylol use.
Continue reading "1,000 People Died Each Month From Trasylol"
New Studies Support Trasylol Risk
Category: Trasylol Discussion
Two studies have been published in the New England Journal of Medicine that support the increased risk of kidney failure following the use of Trasylol. The anti-bleeding drug Trasylol is used during open heart surgery to reduce blood loss. It was pulled from the market after a study was published last year showing the risk of death to be twice that of other drugs in the same class. Researchers have been trying to analyze data from patients to confirm or disprove the risk.
60 Minutes News Story: Deaths & Kindey Failure Related to Trasylol
Category: Trasylol News
This evening, 60 Minutes, the famous investigative TV news show, reported on medical studies which show that use of the drug Trasylol was linked to acute renal failure and death when used in heart surgeries. The lead story on 60 minutes profiled the heart surgery, kidney failure, amputations and eventual death of Joseph Randone after Trasylol was used. According to the surviving family members, the surgeon alerted them to a story on Trasylol and informed them that he believed Trasylol had been to blame in their father's death.
Read more about the Trasylol complications and the Randone Family's story on InjuryBoard.com.
FDA Reacted to Slowly to Trasylol Threat
Category: Trasylol News
A researcher from San Francisco was working on a study in 2005 that showed that Trasylol increased the risk of kidney failure. Dr. Joseph Mangano performed the study on data from over 5,000 patients. He believes that for every month that the FDA failed to pull Trasylol from the market 1,000 people died after using the drug. Trasylol is used during open heart surgery to reduce bleeding. It took another large study in Canada before the FDA acted though. Following the BART study Trasylol was pulled from the market in November 2007.
ACE Inhibitors Increase Trasylol Risk
Category: Trasylol News
A new report from British researchers is showing that the risks of kidney failure when using Trasylol increased when also used with ACE inhibitors during off-pump open heart surgery. Off-pump surgery meaning the heart is beating and no bypass machine is used. Patients that received Trasylol during surgery on a bypass machine had no increase risk of injury. Aprontinin is the generic name for Trasylol.
What to do about Adverse Drug Reactions
Category: Trasylol Discussion
Adverse drug reactions, especially those that are coupled with a major surgery, can be difficult to detect. The recent news that Trasylol may cause kidney failure, heart attacks, and strokes, has many patients wondering what to do next. There is a reported 106,000 deaths in the United States from adverse drug reactions each year.
Duluth Health System Bans Trasylol Pens
Category: Trasylol News
A health-care system in Duluth, Minnesota has banned all drug related freebies from their offices and buildings. That means no more pens or pads of paper labeled with names such as Trasylol, Vytornin, or Avandia. The SMDC Health System Administrators didn't want doctors influenced by the freebies.
Risks Even with Established Drugs
Category: Trasylol Discussion
Even after a prescription drug has been on the market for many years there is no guarantee that they are safe. Recent drugs to go under the microscope are Vytorin, Trasylol, and Avandia. Vytorin is a cholesterol lowering drugs which studies say does not decrease the risk of heart attacks and strokes.
Trasylol in Open Heart Surgery
Category: Trasylol Discussion
According to the Food and Drug Administration (FDA) Trasylol has been approved for use in coronary artery bypass graft surgery (CABG) which is commonly known as heart bypass surgery. This is the only use of the drug that the FDA has approved. In November of 2007 the FDA asked Bayer for a marketing suspension of the drug following preliminary data from the BART study in Canada. The data was showing an increased risk of death following Trasylol use.
Trasylol for Heart Bypass Surgery Only
Category: About Trasylol
According to Bayer and the FDA, the anti-bleeding drug Trasylol is only approved for heart bypass surgery. Many times Trasylol was used during heart valve replacement surgery though. Trasylol was pulled from the market in November after reports of increased risk of death after using the drug.
CHM Suspends Trasylol License
Category: Trasylol News
The Commission for Human Medicine has reviewed data from the BART study that was performed in Canada on the anti-bleeding drug Trasylol. Trasylol was recalled in early November after the BART study showed the drug increased the risk of death by fifty percent over other drugs in the same class. The CHM announced they have suspended Trasylol's license.
Trasynin Also Contains Aprotinin
Category: About Trasylol
Trasylol was recalled in November after reports that it increases the risk of death by 50 percent over drugs in the same class. It is used to stop bleeding during open heart surgery. The active component in Trasylol is Aprotinin. Aprotinin is also found in the drug Trasynin. It was also recalled by Bayer.
Aprotinin Banned in China
Category: Trasylol News
Aprotinin is the generic name for Trasylol. Aprotinin has been used in China as a post-surgery drug used to control bleeding. It is not manufactured by Bayer in China. Due to recent reports that Trasylol was recalled around the world, the Chinese government has banned the use of aprotinin.
Did Your Surgeon Use Trasyol?
Category: Trasylol Discussion
While undergoing surgery it may be unusual for a doctor or surgeon to discuss the exact medications and details of every procedure that will be performed on you. If you or a loved one has undergone open heart surgery in the last five years than you may want to find out what drugs were used, especially if there were any complications.
February JAMA Report Showed Trasylol Risk
Category: Trasylol Discussion
A study published in the February 2007 edition of the Journal of the American Medical Association (JAMA) showed an increased risk of using the recalled drug Trasylol that continued for at least five years after surgery. The study analyzed data from 4374 patients. The researchers were calculating the survival rate of patients at six weeks, six months, and every year for five years.
Continue reading "February JAMA Report Showed Trasylol Risk"
Was Trasylol Pulled Over Lawsuits?
Category: Trasylol Lawsuits
A man died after Trasylol was used in his open heart surgery. His widow filed a lawsuit against the manufacturer of the drug and the drug was pulled from the market shortly thereafter. Bayer claims they are just evaluating the drugs safety after a Canadian study showed the risk of death is increased by 50 percent after use of the drug.
Long Island Hospital Limited the Use of Trasylol
Category: Trasylol News
A hospital in Long Island limited the use of the anti-bleeding drug Trasylol in 2006, long before the drug was pulled from the market. Long Island Jewish surgeons have only used Trasylol in a small number of cases in order to limit risks to their patients. The drug was pulled from the market after a study showed an increased risk of kidney failure, heart attack and strokes.
Continue reading "Long Island Hospital Limited the Use of Trasylol"
United Kingdom Commission Recommends Suspension of Trasylol
Category: Trasylol News
A commission in the United Kingdom has recommended that a marketing suspension for the anti-bleeding drug Trasylol until further studies can be done. The Commission for Human Medicine (CHM) will be watching a European study to see what action to take next. The study is expected to take 3 months.
Continue reading "United Kingdom Commission Recommends Suspension of Trasylol"
How Does Trasylol Work?
Category: About Trasylol
Trasylol has been used in heart surgeries around the world since 1993. It is a popular anti-bleeding drug and has been used on potentially millions of patients. It had been approved by the FDA for use in heart bypass surgeries.
Trasylol May be Recalled in Europe
Category: Trasylol News
Trasylol has been pulled from the market in the United States and regulators in Europe are posed to do the same. The European Medicines Agency's Committee for Medicinal Products for Human Use has been researching the results of a Canadian study that prompted pulling Trasylol from much of the world's market. The Committee has advised that pulling the drug was the correct action.
Closer Look at Trasylol Study
Category: About Trasylol
There has much in the news lately about a Canadian study that ended with Trasylol being pulled from the market. The anti-bleeding drug made by Bayer AG was being studied, along with two other drugs in the same class. Researchers wanted to show that they all had the same risk level when used during heart surgery to stop bleeding. The Blood Conservation using Antifibrinolytics in a Randomized Trial (BART) study examined data from nearly 3,000 patients in Canada. Trasylol is also known by the name Aprotinin.